Skip to content
LATEST
Health

Oral GLP-1 Medication Demonstrates Consistent Weight Loss Efficacy Across Menopausal Stages

New clinical data confirms that the oral GLP-1 medication orforglipron effectively promotes weight loss in women across all menopausal stages.

Oral GLP-1 Medication Demonstrates Consistent Weight Loss Efficacy Across Menopausal Stages

Clinical data indicates that the oral GLP-1 receptor agonist orforglipron facilitates weight loss of up to 14% in women, regardless of menopausal status. The analysis, derived from the ATTAIN-1 and ATTAIN-2 trials, confirms efficacy across premenopausal, perimenopausal, and postmenopausal cohorts.

Participants treated with the medication also achieved reductions in waist circumference of up to 12.5 centimeters. These findings suggest a significant improvement in body fat distribution, which is a key indicator for mitigating risks associated with cardiovascular disease and type 2 diabetes.

The study highlights the drug's utility for patients facing metabolic challenges during the menopause transition, a period typically associated with increased difficulty in weight management. The oral administration of the treatment provides a logistical alternative to existing injectable GLP-1 therapies currently on the market.

More stories

Latest news